Wei J Wang, Sa A Wang, Hong Fang, Qing Wei, Jeffrey L Jorgensen, Shimin Hu, Jie Xu, Shaoying Li, Guilin Tang, Zhenya Tang, L Jeffrey Medeiros, Wei Wang
{"title":"非典型免疫型慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的免疫表型、细胞遗传学和突变特征","authors":"Wei J Wang, Sa A Wang, Hong Fang, Qing Wei, Jeffrey L Jorgensen, Shimin Hu, Jie Xu, Shaoying Li, Guilin Tang, Zhenya Tang, L Jeffrey Medeiros, Wei Wang","doi":"10.1002/cyto.b.22248","DOIUrl":null,"url":null,"abstract":"<p><p>Flow cytometric analysis plays an important role in the diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Most CLL cases show a typical immunophenotype characterized by the expression of CD5, CD23, CD43, ROR1, and CD200, along with dim expression of B-cell markers. However, some show an atypical immunophenotype. The immunophenotypic, cytogenetic, and mutational profiles of atypical CLL are not well characterized. In this study, we aim to address these gaps by analyzing a cohort of 270 CLL cases with a focus on those with atypical immunophenotypes. Their detailed immunophenotype as assessed by flow cytometry is presented along with cytogenetics and mutational data. Fifty-three (19.6%) cases exhibited an atypical immunophenotype. The common atypical immunophenotypic features detected included increased CD20 in 17 (32.1%), negative CD43 in 17 (32.1%), negative ROR1 in 16 (30.1%), and increased surface light chain in 11 (20.8%) cases. Trisomy 12 was more frequently detected in atypical versus typical CLL cases (58.5% vs. 20.7%, p < 0.01), including those with decreased to negative expression of CD5, CD23, CD43, and ROR1, and increased expression of CD20 and CD22. Cases with increased CD20 expression more often had mutated IGHV. BIRC3 is the most frequent mutation in the atypical CLL group, and alterations in BIRC3 (p = 0.02), KRAS (p = 0.03), NRAS (p < 0.01), KMT2D (p < 0.01), and SMARCA4 (p = 0.02) were more frequently detected in atypical CLL when compared to typical CLL. In summary, approximately 20% of CLL cases show an atypical immunophenotype, and these cases have cytogenetic abnormalities and mutation profiles that differ in frequency from typical CLL cases. Recognition of the immunophenotype of atypical CLL can be helpful in the diagnosis and differential diagnosis in low-grade B-cell neoplasms.</p>","PeriodicalId":10883,"journal":{"name":"Cytometry Part B: Clinical Cytometry","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Immunophenotypic, cytogenetic, and mutational features of chronic lymphocytic leukemia/small lymphocytic lymphoma with atypical immunophenotype.\",\"authors\":\"Wei J Wang, Sa A Wang, Hong Fang, Qing Wei, Jeffrey L Jorgensen, Shimin Hu, Jie Xu, Shaoying Li, Guilin Tang, Zhenya Tang, L Jeffrey Medeiros, Wei Wang\",\"doi\":\"10.1002/cyto.b.22248\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Flow cytometric analysis plays an important role in the diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Most CLL cases show a typical immunophenotype characterized by the expression of CD5, CD23, CD43, ROR1, and CD200, along with dim expression of B-cell markers. However, some show an atypical immunophenotype. The immunophenotypic, cytogenetic, and mutational profiles of atypical CLL are not well characterized. In this study, we aim to address these gaps by analyzing a cohort of 270 CLL cases with a focus on those with atypical immunophenotypes. Their detailed immunophenotype as assessed by flow cytometry is presented along with cytogenetics and mutational data. Fifty-three (19.6%) cases exhibited an atypical immunophenotype. The common atypical immunophenotypic features detected included increased CD20 in 17 (32.1%), negative CD43 in 17 (32.1%), negative ROR1 in 16 (30.1%), and increased surface light chain in 11 (20.8%) cases. Trisomy 12 was more frequently detected in atypical versus typical CLL cases (58.5% vs. 20.7%, p < 0.01), including those with decreased to negative expression of CD5, CD23, CD43, and ROR1, and increased expression of CD20 and CD22. Cases with increased CD20 expression more often had mutated IGHV. BIRC3 is the most frequent mutation in the atypical CLL group, and alterations in BIRC3 (p = 0.02), KRAS (p = 0.03), NRAS (p < 0.01), KMT2D (p < 0.01), and SMARCA4 (p = 0.02) were more frequently detected in atypical CLL when compared to typical CLL. In summary, approximately 20% of CLL cases show an atypical immunophenotype, and these cases have cytogenetic abnormalities and mutation profiles that differ in frequency from typical CLL cases. Recognition of the immunophenotype of atypical CLL can be helpful in the diagnosis and differential diagnosis in low-grade B-cell neoplasms.</p>\",\"PeriodicalId\":10883,\"journal\":{\"name\":\"Cytometry Part B: Clinical Cytometry\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-08-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cytometry Part B: Clinical Cytometry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/cyto.b.22248\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytometry Part B: Clinical Cytometry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cyto.b.22248","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
Immunophenotypic, cytogenetic, and mutational features of chronic lymphocytic leukemia/small lymphocytic lymphoma with atypical immunophenotype.
Flow cytometric analysis plays an important role in the diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Most CLL cases show a typical immunophenotype characterized by the expression of CD5, CD23, CD43, ROR1, and CD200, along with dim expression of B-cell markers. However, some show an atypical immunophenotype. The immunophenotypic, cytogenetic, and mutational profiles of atypical CLL are not well characterized. In this study, we aim to address these gaps by analyzing a cohort of 270 CLL cases with a focus on those with atypical immunophenotypes. Their detailed immunophenotype as assessed by flow cytometry is presented along with cytogenetics and mutational data. Fifty-three (19.6%) cases exhibited an atypical immunophenotype. The common atypical immunophenotypic features detected included increased CD20 in 17 (32.1%), negative CD43 in 17 (32.1%), negative ROR1 in 16 (30.1%), and increased surface light chain in 11 (20.8%) cases. Trisomy 12 was more frequently detected in atypical versus typical CLL cases (58.5% vs. 20.7%, p < 0.01), including those with decreased to negative expression of CD5, CD23, CD43, and ROR1, and increased expression of CD20 and CD22. Cases with increased CD20 expression more often had mutated IGHV. BIRC3 is the most frequent mutation in the atypical CLL group, and alterations in BIRC3 (p = 0.02), KRAS (p = 0.03), NRAS (p < 0.01), KMT2D (p < 0.01), and SMARCA4 (p = 0.02) were more frequently detected in atypical CLL when compared to typical CLL. In summary, approximately 20% of CLL cases show an atypical immunophenotype, and these cases have cytogenetic abnormalities and mutation profiles that differ in frequency from typical CLL cases. Recognition of the immunophenotype of atypical CLL can be helpful in the diagnosis and differential diagnosis in low-grade B-cell neoplasms.
期刊介绍:
Cytometry Part B: Clinical Cytometry features original research reports, in-depth reviews and special issues that directly relate to and palpably impact clinical flow, mass and image-based cytometry. These may include clinical and translational investigations important in the diagnostic, prognostic and therapeutic management of patients. Thus, we welcome research papers from various disciplines related [but not limited to] hematopathologists, hematologists, immunologists and cell biologists with clinically relevant and innovative studies investigating individual-cell analytics and/or separations. In addition to the types of papers indicated above, we also welcome Letters to the Editor, describing case reports or important medical or technical topics relevant to our readership without the length and depth of a full original report.